Lilly begins phase 3 testing of an amylin drug on top of weekly incretins

Eli Lilly has started phase 3 testing of eloralintide, an experimental amylin receptor agonist, as an add-on therapy for people already taking a weekly incretin medicine for obesity or overweight. The trial, registered on ClinicalTrials.gov as NCT07392190, is enrolling adults with persistent obesity or overweight who are on stable weekly incretin treatment and randomizing them to receive either eloralintide or placebo ^[1].

The study, known as ENLIGHTEN-6, plans to enroll about 900 adults and will run for roughly 80 weeks ^[1]. Participants must already be on a stable dose of a weekly incretin therapy before joining, meaning the trial is not testing eloralintide by itself but rather testing what happens when it is layered on top of an existing GLP-1 or dual-agonist regimen ^[1]. Eloralintide, also known by its development code LY3841136, works on a different hormone pathway than semaglutide or tirzepatide. It targets amylin receptors rather than GLP-1 or GIP receptors ^[1].

Lilly's public pipeline confirms that this add-on approach is a distinct development program. The company lists "Eloralintide Incretin Add-On" as a phase 3 project in obesity, separate from eloralintide's own phase 3 programs in obesity, obstructive sleep apnea, and osteoarthritis pain ^[2]. The pipeline also shows tirzepatide, sold as Mounjaro and Zepbound, moving through its own late-stage trials for cardiovascular outcomes, MASLD, and type 1 diabetes, and orforglipron, sold as Foundayo, in regulatory review for diabetes and in phase 3 testing for conditions such as hypertension and obstructive sleep apnea ^[2]. Taken together, the pipeline suggests Lilly sees future obesity treatment as involving combinations of drugs rather than a single medicine used alone.

Why it matters for patients

For people currently taking Mounjaro, Zepbound, Ozempic, Wegovy, or Rybelsus, this trial does not change anything about their current prescriptions. Eloralintide is not approved and is only now entering the kind of large, multi-year study needed before the Food and Drug Administration would consider it ^[1]. But the trial design matters because it tests a scenario many patients and doctors already wonder about: what happens if you add a second type of obesity drug to a weekly incretin that has plateaued in effect. The answer is not yet known. Whether eloralintide adds meaningful additional weight loss, and whether it does so safely alongside a weekly incretin, are exactly the questions ENLIGHTEN-6 is designed to answer over its roughly 80-week course ^[1].

It is also worth noting what is not disclosed. The specific dose or doses of eloralintide being tested, the exact incretin therapies participants are allowed to be on, and the trial's primary measured outcome are not described in the available registration summary ^[1]. Patients should not assume any particular combination will become available soon, since phase 3 trials commonly take one to two years to complete enrollment and follow-up before results are reported.

What happens next

ENLIGHTEN-6 has begun enrolling its target of about 900 participants, with treatment lasting approximately 80 weeks per participant ^[1]. Results would typically follow completion of the trial's primary endpoint period, though no specific readout date is available in the current sources. Lilly's broader pipeline shows related eloralintide programs, including obesity, obstructive sleep apnea, and osteoarthritis pain indications, also in phase 3, meaning multiple studies of this drug are moving forward at the same time ^[2].